Laureate Pharma, Inc. has renewed its agreement with Cytogen Corp. for the cGMP manufacture of ProstaScint, Cytogen's proprietary monoclonal antibody immunoconjugate that is used for imaging in patients diagnosed with prostate cancer. Under the agreement, Laureate will provide cGMP protein production, purification, conjugation of Cytogen's proprietary linker chelator and aseptic filling services to support commercial ProstaScint requirements. Terms of the agreement were not disclosed.

"We are delighted by the confidence that Cytogen has shown in Laureate by continuing to utilize our specialized experience in the manufacture of ProstaScint," said Robert J. Broeze, president and chief executive officer of Laureate. "We have developed a great working relationship with our colleagues at Cytogen and we look forward to helping them achieve their manufacturing objectives."

Laureate has been manufacturing ProstaScint at its cGMP manufacturing facility in Princeton, NJ for more than 10 years.